Moskowitz, A. J., Schöder, H., Yahalom, J., McCall, S. J., Fox, S. Y., Gerecitano, J., Grewal, R., Hamlin, P. A., Horwitz, S., Kobos, R., Kumar, A., Matasar, M., Noy, A., Palomba, M. L., Perales, M., Portlock, C. S., Sauter, C., Shukla, N., Steinherz, P., Straus, D., Trippett, T., Younes, A., Zelenetz, A., & Moskowitz, C. H. (n.d.). pET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet oncology, 16(3), 284–292. http://access.bl.uk/ark:/81055/vdc_100050919898.0x00001c